TMIC-04. GLIOBLASTOMA-ASSOCIATED MYELOID CELLS DISPLAY NONPOLARIZED M0 MACROPHAGE PHENOTYPE
Konrad Gabrusiewicz(Cell Medica (Switzerland)), Amy B. Heimberger(Northwestern University), Qianghu Wang(Nanjing Brain Hospital), Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center), Ravesanker Ezhilarasan(Post Graduate Institute of Medical Education and Research), Ganesh Rao(Baylor College of Medicine), Nasser K. Yaghi(The University of Texas MD Anderson Cancer Center), Wei Li(University of California, Irvine), Shouhao Zhou(Pennsylvania State University), Luke M. Healy(Montreal Neurological Institute and Hospital), Neal Huang(The University of Texas MD Anderson Cancer Center), Jeffrey S. Weinberg(The University of Texas MD Anderson Cancer Center), Jack P. Antel(Montreal Neurological Institute and Hospital), Erik P. Sulman(NYU Langone Health), Sujit S. Prabhu(The University of Texas MD Anderson Cancer Center), Brandon Liebelt(The University of Texas Health Science Center at San Antonio), Michael A. Curran(The University of Texas MD Anderson Cancer Center), Blanca Rodríguez(Universidad de Oviedo), Krishna Bhat(WinnMed), Amit Bar‐Or(University of Pennsylvania), Jun Wei(University of Bath), Rivka R. Colen(The University of Texas MD Anderson Cancer Center), Raymond Sawaya(American University of Beirut Medical Center), Yuuri Hashimoto(Daiichi-Sankyo (Japan)), Sourindra Maiti(The University of Texas MD Anderson Cancer Center), Janet Bruner(The University of Texas MD Anderson Cancer Center), Lauren A. Langford(The University of Texas MD Anderson Cancer Center), Gregory Fuller, Ginu Thomas(The University of Texas MD Anderson Cancer Center), Ahmed Elakkad(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k